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Interleukin (IL)-10 is a cytokine that modulates both innate and adaptive 
immunity, primarily by exerting antiinfl  ammatory effects. IL-10 was originally 
thought to be produced only by T helper (Th)2 cells, but is now known to be 
made by a variety of cell types. During many infections, CD4+ T cells produce 
both interferon (IFN)-γ, the signature Th1 cytokine, and IL-10. New data now 
show that the IL-10 produced by effector Th1 cells helps limit the collateral 
damage caused by exaggerated infl  ammation. But this control may also limit 
the effectiveness of the immune response, resulting in a failure to fully 
eliminate pathogens.
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IL-10 suppresses many functions of natu-
ral killer (NK) cells and T cells, primarily 
by preventing antigen-presenting cells 
(APCs) from producing proinfl  amma-
tory cytokines, such as IL-12, and from 
up-regulating molecules involved in 
antigen presentation and lymphocyte 
  activation (1). IL-10 prevents the up-
regulation of many genes in phagocytic 
cells and dendritic cells (DCs) that are 
normally induced by stimulation via 
Toll-like receptors (TLRs) or other pat-
tern recognition receptors. Although 
most of IL-10’s eff  ects are suppressive, 
this cytokine also exerts some immune-
stimulating eff  ects, such as promoting the 
generation of cytotoxic T lymphocytes, 
activating B cells (1), and up-regulating a 
small number of genes in TLR-activated 
phagocytic cells and DCs (2).
Upon binding to its two-chain re-
ceptor, IL-10 acts primarily by pre-
venting gene transcription through a 
mechanism that requires STAT3 and 
de novo protein synthesis but is other-
wise poorly understood (3, 4). Many 
cell types can produce IL-10, including 
phago  cytic cells, conventional DCs, T 
cells, B cells, and NK cells (1). IL-10 was 
originally described as a cytokine pro-
duced specifi  cally by CD4+ Th2 cells, 
but later studies showed that it was se-
creted by both Th1 and Th2 cells. IL-10 
is also made by CD4+ Foxp3+ CD25+ 
“natural” regulatory T (T reg) cells 
and IL-10–induced CD4+ T reg cells 
(Tr1 cells) (1). In this issue, two papers 
(Jankovic et al. [5] p. 273 and Ander-
son et al. [6] p. 285) investigate the 
  cellular origin of IL-10 in Toxoplasma 
gondii– and Leishmania major–infected 
animals. These new data show that al-
though most of the cell types mentioned 
above produce IL-10 during infections, 
the IL-10 responsible for limiting in-
fl  ammatory pathology during T. gondii 
infection and for maintaining a chronic 
nonresolving infection with L. major 
is produced by CD4+ Foxp3− CD25− 
  antigen-specifi  c Th1 cells (which also pro-
duced IFN-γ), rather than by Th2 cells, 
T reg cells, or innate cells.
How IL-10 helps protect
Many mechanisms are in place to pre-
vent exaggerated infl  ammatory and im-
mune responses and thus protect the 
host from immune-mediated damage. 
But in many cases, IL-10 has proven to 
be an essential factor in this protection. 
For example, animals which are geneti-
cally defi  cient for IL-10 or are treated 
with antibodies that neutralize IL-10 
functions die rapidly when infected 
with pathogens such as T. gondii or Try-
panosoma cruzi. In these models, death is 
caused by the overproduction of pro-
infl  ammatory cytokines, despite the fact 
that the infection is controlled as well as 
or better than in wild-type animals (7, 8). 
During infection with viruses, such 
as lymphocyte choriomeningitis virus, 
the production of IL-10 maintains a 
chronic, nonhealing infection, and neu-
tralization of IL-10 allows the animals to 
clear the virus (9, 10). In tumor-bearing 
animals, the profound anergy and unre-
sponsiveness of tumor-infi  ltrating DCs 
and macrophages is rapidly reversed by 
neutralization of IL-10 (11). Injection 
of TLR ligands into the tumors of these 
anti–IL-10–treated animals induces a 
rapid hemorrhagic necrosis that may 
  result in the complete elimination of 
the tumors (12).
Although IL-10 is a secreted cytokine 
that can have systemic eff  ects, its cellular 
origin has been shown to profoundly 
  aff  ect the resulting immune regulation. 
Mice with a T cell–specifi  c inactivation 
of the IL-10 gene, for example, succumb 
to severe immunopathology upon infec-
tion with T. gondii, similar to mice with 
complete IL-10 defi   ciency, but have 
normal innate responses to lipopolysac-
charide (LPS) (13). Because the eff  ects of 
IL-10 on T cells are primarily indirect, the 
cells that respond to the T cell–produced 
IL-10 in this model are probably the 
  accessory cells or APCs with which the 
T cells interact. Conversely, mice in which 
IL-10 is inactivated in phagocytic cells 
(macrophages and neutrophils) are hy-
perresponsive to LPS but not to CpG-
containing oligonucleotides, suggesting 
that CpG induce IL-10 production by 
TLR9+ cells other than macrophages, 
such as B cells or DCs (14). These data sug-
gest that the identity of both the IL-10–
producing cell and the IL-10–reponding 
cell aff  ects the resulting response.
Regulation of IL-10 production 
in T cells
In many chronic infections in human 
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can produce high levels of both IL-10 
and IFN-γ (for review see reference 15). 
For example, both cytokines are pro-
duced by short term CD4+ T cell clones 
expanded from bronchoalveolar lavage 
fl  uid, but not from peripheral blood, of 
patients with active tuberculosis (16). 
Although the nature of these cells has 
not been fully characterized, the pro-
duction of high levels of both cytokines 
in the absence of  signifi  cant levels of 
other Th2 cytokines, suggests that these 
cells are Th1 cells, rather than Th2 cells 
or T reg cells (15). In vitro, human 
CD4+ and CD8+ T cell clones that 
produce high levels of both IFN-γ and 
IL-10 could be generated by expanding 
the cells with polyclonal stimulation in 
the presence of IL-12 (17). In that 
study, IL-12 was required within the 
fi  rst 3 days after proliferation was in-
duced, and for at least 2 weeks there-
after, for the cells to be stably primed for 
the production of both cytokines upon 
restimulation. This priming was main-
tained even if the cells had been ex-
panded for several weeks in the absence 
of IL-12. The presence of IL-4 dur-
ing Th1 priming completely prevented 
subsequent IL-10 production but only 
modestly aff   ected subsequent IFN-γ 
production. Conversely, IL-4 was needed 
for IL-10 production by T cells primed 
under Th2 conditions. Similar to the 
  eff  ect of IL-12 in priming IFN-γ–IL-
10 coproducing Th1 cells, type I IFN 
has been shown to induce naive cord 
blood CD4+ T cells to diff  erentiate 
into Tr1 cells that produce both IL-10 
and IFN-γ (18). Because both IL-12 
and type I IFN activate STAT4 in hu-
man T cells, it is possible that this 
transcription factor is partly responsi-
ble for the priming of both the IL10 
and the IFNγ genes in human T cells. 
Overall, the data in both humans 
and mice suggests that both Th1 and 
Th2 cells can produce IL-10 but that 
  different regulatory mechanisms are 
at play.
Interestingly, the chromatin organi-
zation of the IL10 gene in Th1 and Th2 
cells is diff  erent from that of the IL4 
and IFNγ genes. The IL10 promoter 
and some putative regulatory elements 
are silenced in Th1 cells (19, 20). The 
remainder of the IL10 locus in both 
Th1 and Th2 cells, however, contains 
hypersensitivity sites not present in na-
ive T cells (19–22). The IL4 promoter 
is also silenced in Th1 cells but, unlike 
the IL10 locus, contains no hypersensi-
tivity sites other than those present in 
naive T cells (23). The IFNγ locus is 
similarly silenced in Th2 cells (23). 
Thus, it has been suggested that the 
IL10 locus may be in a reversible his-
tone deacetylase–responsive state in 
Th1 cells (20), which may permit its re-
activation in situations such as continu-
ous stimulation by chronic infection 
or maximal in vitro activation in the 
presence IL-12 (17). The regulation of 
IL-10 production has been characterized 
in many cell types, such as Th2 cells, 
macrophages, and DCs, and involves 
both common and cell type–specifi  c 
regulatory elements (21, 22, 24). It re-
mains to be established whether unique 
mechanisms of IL-10 regulation are 
present in Th1 cells.
IL-10 production during acute 
and chronic infections
The two papers in this issue address 
which subset of CD4+ T cells produces 
the IL-10 that prevents T. gondii–induced 
mortality and suppresses infl  ammation 
during chronic cutaneous infections with 
L. major (5, 6).
A previous study had identifi  ed the 
CD4+ T cells that produce both IL-10 
and IFN-γ during T. gondii infection, 
and showed that cytokine induction in 
these cells did not require IL-12, IL-18, 
IL-23, STAT4, IL-4, STAT6, or IFN-γ 
(25 and unpublished data). IL-10 pro-
duction by these T cells was required to 
prevent early mortality caused by ex-
cessive infl  ammation. Here, Jankovic 
et al. (5) show that T cell–produced IL-10 
is required for survival during both the 
acute and chronic phases of T. gondii 
infection (Fig. 1, A–C). The authors 
clearly identifi  ed the IL-10–producing 
T cells as activated, T-bet+ Th1 cells 
that are distinct from Th2 cells, natural 
Foxp3+ T reg cells, and other subsets of 
induced T reg cells. These Th1 T cells 
were fully functional eff  ector Th1 cells, 
as demonstrated by their ability to in-
duce nitric oxide–mediated parasite 
  destruction by macrophages, which was 
comparable to that of Th1 cells produc-
ing IFN-γ only. The production of 
IL-10 was transient, observed in only a 
fraction of the IFN-γ–producing cells, 
and was induced more rapidly from re-
cently activated than from resting cells 
(5). The instability of IL-10 synthesis, 
Figure 1.  T. gondii infection in C57BL/6 
mice. (A) In intact animals, IFN-γ–producing 
Th1 cells effi  ciently control the infection. Some 
of these Th1 cells also produce IL-10, which 
helps limit the Th1 response and limit infl  am-
mation. (B) Blocking IFN-γ or IL-12 allows the 
infection to proceed unchecked, causing the 
rapid death of the animals. (C) Blocking the 
production of IL-10 by Th1 cells triggers an 
overproduction of proinfl  ammatory cytokines 
by T cells and innate cells, resulting in the 
death of the infected animals, despite 
parasite clearance.COMMENTARY
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which was observed only when the 
Th1 cells were fully activated, likely 
helps prevent sustained IL-10–mediated 
suppression of eff  ector functions, which 
might hamper parasite clearance.
Cutaneous infections with L. major 
(Friedlin strain) can be clinically cured 
by a Th1-mediated mechanism in resis-
tant C57BL/6 mice. A small number 
of parasites can persist, however, and 
a sterile cure can be achieved only if 
IL-10 is neutralized (26). IL-10 is pro-
duced mostly by CD4+ T cells in this 
model, and all of the IL-10–producing 
CD4+ cells at the site of infection, 
and half of those in the draining 
lymph node (LN), also produce IFN-γ 
(26). Other studies have shown that 
during the chronic phase of L. major in-
fection, approximately half of the CD4+ 
T cells at the site of infection are anti-
gen-specifi  c  CD25+ Foxp3+ T reg 
cells, which inhibit the response of 
CD25− eff  ector T cells via both IL-10–
dependent and –independent mecha-
nisms (27, 28). These T reg cells produce 
most of the IL-10 responsible for 
the maintenance of chronic infection, 
whereas CD25− T cells produce most 
of the IFN-γ (27).
Anderson et al. now characterize 
the source of IL-10 in C57BL/6 mice 
infected intradermally with a clinical 
isolate of L. major (NIH/Sd) that pro-
duces heavily infected, nonhealing le-
sions, even in the presence of a vigorous 
Th1 response (6). This experimental 
model is reminiscent of clinical leish-
maniasis, which is characterized by a 
Th1-type response associated with IL-10 
production that, in some cases, fails to 
induce healing or to prevent visceral 
spreading of the infection. In mice in-
fected with L. major NIH/Sd, the IL-10 
produced by T cells, but not by innate 
cells, was required for the suppression 
of the healing response, although most 
of the IL-10 at the lesion site was pro-
duced by innate cells (Fig. 2 A). The 
majority of IL-10 in the draining LNs, on 
the other hand, was produced by T cells, 
including both CD25+ Foxp3+ T reg 
cells and CD4+ CD25− Foxp3− T cells. 
A majority of the latter cells also pro-
duced IFN-γ (6).
Adoptive transfer experiments using 
these two IL-10–producing cell subsets 
showed that, surprisingly, only the 
IL-10 produced by the CD4+ CD25− 
Foxp3− T cells suppressed the heal-
ing response, whereas IL-10 from the 
CD25+ Foxp3+ T reg cells was ineff  ec-
tive (6) (Fig. 2 B). Depletion of the 
T reg cells did, however, result in an 
increased parasite burden, suggesting 
that these cells promoted host resistance 
against this strain of L. major, possibly 
by suppressing a deleterious Th2 response 
and/or by decreasing IL-10 production 
by the Th1 cells (Fig. 2 C).
These results indicate that the ability 
of IL-10 to suppress the in vivo im-
mune response depends not only on 
whether the cytokine is produced by 
innate cells or immune CD4+ T cells, 
but also on the specifi  c type of CD4+ 
T cell. These fi  ndings are diffi   cult to in-
terpret and could be explained either by 
a diff  erential ability of regulatory and 
eff  ector CD4+ T cells to migrate into 
the LNs or to localize in diff  erent re-
gions of the LNs. It is also possible that 
IL-10 may need to be produced at the 
site of cell–cell contact during the cog-
nate interaction between the eff  ector 
CD4+ T cells and the APCs. However, 
it is also possible that the IL-10 pro-
duced by T reg cells is effi   cient in an-
tagonizing the Th1 response, but that 
this eff  ect is functionally negated by the 
concurrent removal of the parasite-
friendly Th2 response.
Concluding remarks
These data suggest that activated eff  ec-
tor Th1 cells produce IL-10 as a means 
of preventing collateral immune dam-
age—a mechanism of self control. But 
this mechanism can also be used by 
pathogens to prevent their elimination. 
Although IL-12 is not necessary for the 
generation of IL-10–producing Th1 
Figure 2.  L. major NIH/Sd infection in C57BL/6 mice. (A) In intact 
animals, IFN-γ–producing Th1 cells only partially control the infection, 
and nonhealing lesions are established. (B) Blocking the production of IL-10 
by Foxp3− Th1 cells increases the Th1 effector response, which helps clear 
the infection. (C) Depleting Foxp3+ T reg cells increases the parasite 
burden in parallel with the production of IL-10 and Th2 cytokines, 
resulting in increased susceptibility to infection.242  IL-10–PRODUCING TH1 CELLS | Trinchieri
cells in T. gondii–infected animals, it is 
interesting that in cultures of human 
T cells, extreme Th1 polarization in the 
presence of high concentration of IL-12 
induces apparent irreversible priming 
for the production of high levels of both 
IL-10 and IFN-γ (17). IL-12–induced 
IFN-γ was also recently shown to pro-
vide a signal for the reactivation of IL-10 
in Th1 cells from T. gondii–infected 
mice (29). In that study, IL-10 reactiva-
tion was mediated by the IFN-γ–driven 
expression of inducible costimulator li-
gand (ICOS-L) on non–T cells (29). 
Interestingly, plasmacytoid DCs, which 
themselves do not produce IL-10, have 
been shown to promote IL-10 secre-
tion from CD4+ and CD8+ T cells via 
ICOS-L expression induced during 
DC maturation (30). Indeed, plasmacy-
toid DCs are emerging as essential APCs 
for the induction of antigen-specifi  c 
tolerance in several experimental mod-
els (31, 32).
The challenge is now to character-
ize the specifi  c molecular mechanisms 
that lead to priming of the IL10 gene in 
Th-1 and Th2 cells and to IL-10 reacti-
vation and expression in Th1-commit-
ted cells. It will also be important to 
identify the specifi  c role of diff  erent 
subsets and maturation stages of APCs 
and DCs in regulating the diff  erentia-
tion of eff  ector T cells and T reg cells, 
and in controlling feedback mecha-
nisms, and to determine the role of the 
diff   erent costimulatory pathways in 
regulating these responses. Knowledge 
of these mechanisms may allow us to 
identify new targets of intervention for 
the treatment and prevention of infec-
tious diseases. Some of these regulatory 
mechanisms might also be involved in 
the immunosuppressive environment 
seen in tumors, and their study could 
provide new mechanistic insights into 
cancer immunology.
I would like to thank Dr. Yasmine Belkaid for advice 
and discussions.
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